Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Engell, T.
Right arrow Articles by Platz, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Engell, T.
Right arrow Articles by Platz, P.
NEUROLOGY 1982;32:1043
© 1982 American Academy of Neurology

HLA and heterogeneity of multiple sclerosis

Tine Engell, Niels E. Raun, Mogens Thomsen and Per Platz

Neurological Department, Municipal Hospital (Drs. Engell and Raun), and The Tissue Typing Laboratory of the Blood Grouping Department (Drs. Thomaen and Platz), University Hospital (Rigshos- pitalet), Copenhagen, Denmark.

Age at onset, debut symptoms, optic nerve signs, and severity of symptoms were evaluated from the medical records of 135 patients with MS. HLA-D/DR2 was significantly more frequent in rapidly progressive MS, and D/DR2 seemed to confer both susceptibility to the disease and to more rapid progression. However, D/DR3 seemed to protect against rapid progression.

Address correspondence and reprint requests to Dr. Platz, Tissue Typing Laboratory, State University Hospital (Rigshospitalet), Blegdamsvej 9, DK-2100 Copenhagen Ø, Denmark.

This study was supported by grants from the Danish Multiple Sclerosis Society and the Warwara Larsen Foundation.

Accepted for publication February 10, 1982.




This article has been cited by other articles:


Home page
 Proc. Natl. Acad. Sci. USAHome page
G. C. DeLuca, S. V. Ramagopalan, B. M. Herrera, D. A. Dyment, M. R. Lincoln, A. Montpetit, M. Pugliatti, M. C. N. Barnardo, N. J. Risch, A. D. Sadovnick, et al.
An extremes of outcome strategy provides evidence that multiple sclerosis severity is determined by alleles at the HLA-DRB1 locus
PNAS, December 26, 2007; 104(52): 20896 - 20901.
[Abstract] [Full Text] [PDF]

Home page
 Arch NeurolHome page
E. M. Frohman, M. Filippi, O. Stuve, S. G. Waxman, J. Corboy, J. T. Phillips, C. Lucchinetti, J. Wilken, N. Karandikar, B. Hemmer, et al.
Characterizing the Mechanisms of Progression in Multiple Sclerosis: Evidence and New Hypotheses for Future Directions
Arch Neurol, September 1, 2005; 62(9): 1345 - 1356.
[Abstract] [Full Text] [PDF]

Home page
 Mult SclerHome page
K Schreiber, A B Oturai, L P Ryder, H O Madsen, O S Jorgensen, A Svejgaard, and P S Sorensen
Disease severity in Danish multiple sclerosis patients evaluated by MRI and three genetic markers (HLA-DRB1*1501, CCR5 deletion mutation, apolipoprotein E)
Multiple Sclerosis, August 1, 2002; 8(4): 295 - 298.
[Abstract] [PDF]

Home page
 BrainHome page
The Multiple Sclerosis Genetics Group, L. F. Barcellos, J. R. Oksenberg, A. J. Green, P. Bucher, J. B. Rimmler, S. Schmidt, M. E. Garcia, R. R Lincoln, M. A. Pericak-Vance, et al.
Genetic basis for clinical expression in multiple sclerosis
Brain, January 1, 2002; 125(1): 150 - 158.
[Abstract] [Full Text] [PDF]

Home page
 J Child NeurolHome page
R. C. Woody, R. W. Steele, R. K. Charlton, and V. Smith
Histocompatibility Determinants in Childhood Postinfectious Encephalomyelitis
J Child Neurol, July 1, 1989; 4(3): 204 - 207.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1982 by AAN Enterprises, Inc.